127876-31-7Relevant academic research and scientific papers
NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Page/Page column 26, (2015/06/25)
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
Potential GabaB Receptor Antagonists. V. The Application of Radical Additions to Styrenes to Produce 2-Hydroxysaclofen
Abbenante, Giovanni,Prager, Rolf H.
, p. 1791 - 1800 (2007/10/02)
3-Amino-2-(4-chlorophenyl)-2-hydroxypropanesulfonic acid (2-hydroxysaclofen), and its 2-phenyl analogue have been synthesized by three methods.Two involve the oxygen-catalysed free radical addition of bisulfite to the corresponding 3-aminopropene or 3-pht
Potential GABAB Receptor Antagonists. VI. The Synthesis of Saclofen and Other Sulfonic Acid Derivatives
Abbenante, Giovanni,Prager, Rolf H.
, p. 1801 - 1810 (2007/10/02)
Saclofen, 3-amino-2-(4-chlorophenyl)propanesulfonic acid (3), has been synthesized by two routes.Attempts to hyrogenolyse or dehydrate the 2-hydroxy derivative were unsuccessful, however.Radical sulfonation of 3-amino-1-bromo-2-(4-chlorophenyl)propene gav
